We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00171431
Recruitment Status : Terminated (This study was terminated early in May 2006 due to low patient enrollment)
First Posted : September 15, 2005
Last Update Posted : April 20, 2012
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.

Condition or disease Intervention/treatment Phase
Constipation Predominant Irritable Bowel Syndrome (IBS-C) Drug: Tegaserod Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
Study Start Date : November 2004
Primary Completion Date : May 2006
Study Completion Date : May 2006

Primary Outcome Measures :
  1. To evaluate the effects of tegaserod on motility and small intestinal flow patterns after meal in female patients with IBS-C
  2. by using Multiple Intraluminal Impedance

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female 18 and older
  • IBS-C patients diagnosed on the basis of Rome II criteria
  • Ability to comply with the requirements of the entire study

Exclusion Criteria:

  • Evidence of structural abnormality of the gastrointestinal tract or disease/conditions.
  • Patients with previous gastrointestinal surgery other than appendectomy or cholecystectomy.
  • Evidence of cathartic colon or a history of laxative use, that in the investigator's opinion is consistent with severe laxative dependence such that the patient is likely to require or use laxatives during the study

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00171431

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Novartis

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00171431     History of Changes
Other Study ID Numbers: CHTF919AUS33
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: April 20, 2012
Last Verified: April 2012

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Pathologic Processes
Signs and Symptoms, Digestive
Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs